Matthew Anson

1.1k total citations · 1 hit paper
31 papers, 617 citations indexed

About

Matthew Anson is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Matthew Anson has authored 31 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Matthew Anson's work include Diabetes Treatment and Management (11 papers), Diabetes Management and Research (5 papers) and Pancreatic function and diabetes (5 papers). Matthew Anson is often cited by papers focused on Diabetes Treatment and Management (11 papers), Diabetes Management and Research (5 papers) and Pancreatic function and diabetes (5 papers). Matthew Anson collaborates with scholars based in United Kingdom, Qatar and Denmark. Matthew Anson's co-authors include Amer Harky, Wayne Jacobson, Sam Van Horne, Uazman Alam, Sizheng Steven Zhao, Gema Hernández, Jacob Oleson, Karla K. McGregor, Rayaz A. Malik and Daniel J. Cuthbertson and has published in prestigious journals such as Scientific Reports, Diabetologia and Thorax.

In The Last Decade

Matthew Anson

24 papers receiving 600 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

2025 30 citations Ralf J. Ludwig, Matthew Anson et al. Frontiers in Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Anson United Kingdom	10	224	122	97	76	65	31	617
Amanda Carpenter United States	21	586 2.6×	28 0.2×	13 0.1×	41 0.5×	26 0.4×	38	1.0k
Lili Song China	13	126 0.6×	9 0.1×	21 0.2×	95 1.3×	139 2.1×	61	966
William Smith United Kingdom	21	168 0.8×	21 0.2×	97 1.0×	21 0.3×	91 1.4×	56	1.2k
Esther Hobson United Kingdom	15	365 1.6×	17 0.1×	27 0.3×	86 1.1×	36 0.6×	35	796
Mohammad Mofatteh United Kingdom	14	99 0.4×	50 0.4×	7 0.1×	165 2.2×	29 0.4×	61	780
Laura Comber Ireland	14	58 0.3×	92 0.8×	15 0.2×	24 0.3×	117 1.8×	27	883
Suzy Davies United States	19	12 0.1×	39 0.3×	78 0.8×	109 1.4×	15 0.2×	45	906
Judith Eberhardt United Kingdom	11	15 0.1×	43 0.4×	21 0.2×	108 1.4×	23 0.4×	63	640
Robert C. Brown United States	14	24 0.1×	48 0.4×	19 0.2×	99 1.3×	19 0.3×	55	670
Alessandra Mereu Italy	12	165 0.7×	18 0.1×	31 0.3×	61 0.8×	11 0.2×	33	570

Countries citing papers authored by Matthew Anson

Since Specialization

Citations

This map shows the geographic impact of Matthew Anson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Anson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Anson more than expected).

Fields of papers citing papers by Matthew Anson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Anson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Anson. The network helps show where Matthew Anson may publish in the future.

Co-authorship network of co-authors of Matthew Anson

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Anson. A scholar is included among the top collaborators of Matthew Anson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Anson. Matthew Anson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riley, David R., et al.. (2025). Synergistic associations of metformin and GLP ‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes. Diabetes Obesity and Metabolism. 28(2). 946–959.

Frank, Bernhard, David R. Riley, Matthew Anson, et al.. (2025). Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events, mortality, amputation, infection and suicide: a retrospective cohort study. EClinicalMedicine. 89. 103489–103489.

Anson, Matthew, et al.. (2025). Real‐world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement. Diabetes Obesity and Metabolism. 28(3). 2425–2430.

Riley, David R., et al.. (2025). Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence. Annals of the American Thoracic Society. 22(7). 1042–1052. 2 indexed citations

Ludwig, Ralf J., Matthew Anson, Henner Zirpel, et al.. (2025). A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Frontiers in Pharmacology. 16. 1516126–1516126. 30 indexed citations breakdown →

Riley, David R., Carl Roberts, Theresa Hydes, et al.. (2025). Relative efficacy of GLP ‐1 and GLP ‐1/ GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach. Diabetes Obesity and Metabolism. 28(1). 137–150.

Riley, David R., et al.. (2025). Target Trial Emulations of GLP ‐1 and Dual GLP ‐1/ GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver International. 45(10). e70367–e70367.

Anson, Matthew, David R. Riley, Gema Hernández, et al.. (2024). SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum. Clinical Therapeutics. 46(11). 835–840. 5 indexed citations

Riley, David R., Theresa Hydes, Matthew Anson, et al.. (2024). Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis. Diabetes Obesity and Metabolism. 26(9). 3673–3683. 5 indexed citations

10.

Anson, Matthew, Sizheng Steven Zhao, Gema Hernández, et al.. (2024). Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. EClinicalMedicine. 75. 102777–102777. 20 indexed citations

11.

Marshall, Anne, Jamie Burgess, David R. Riley, et al.. (2024). Small fibre pathology, small fibre symptoms and pain in fibromyalgia syndrome. Scientific Reports. 14(1). 3947–3947. 18 indexed citations

12.

Riley, David R., et al.. (2024). Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data. Diabetes Obesity and Metabolism. 26(10). 4665–4673. 1 indexed citations

13.

Riley, David R., Theresa Hydes, Matthew Anson, et al.. (2024). Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data. Thorax. 80(1). 32–41. 8 indexed citations

14.

Riley, David R., Matthew Anson, Daniel J. Cuthbertson, et al.. (2024). Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis. Diabetes Therapy. 15(4). 833–842. 2 indexed citations

15.

Riley, David R., Matthew Anson, Sizheng Steven Zhao, et al.. (2024). The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes‐related and cancer outcomes. Diabetes Obesity and Metabolism. 27(2). 663–674. 4 indexed citations

16.

Riley, David R., Theresa Hydes, Matthew Anson, et al.. (2024). Metabolic syndrome traits differentially and cumulatively influence micro‐ and macrovascular disease risk in patients with MASLD. Liver International. 44(11). 3031–3049. 9 indexed citations

17.

Anson, Matthew, Alex E. Henney, Sizheng Steven Zhao, et al.. (2024). Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide ‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database. Diabetes Obesity and Metabolism. 26(7). 2606–2623. 8 indexed citations

18.

Lim, Jonathan, Jamie Burgess, Maryam Ferdousi, et al.. (2023). Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers. Diagnostics. 13(17). 2793–2793. 1 indexed citations

19.

Anson, Matthew, Sizheng Steven Zhao, Philip Austin, et al.. (2023). Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity. Clinical Therapeutics. 45(12). 1259–1265. 6 indexed citations

20.

Alam, Uazman, Matthew Anson, Yanda Meng, et al.. (2022). Artificial Intelligence and Corneal Confocal Microscopy: The Start of a Beautiful Relationship. Journal of Clinical Medicine. 11(20). 6199–6199. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact